EssilorLuxottica's Oculomics Pivot: From Eyewear to Med-Tech
H1 2026 results show a strategic acceleration into healthcare, with a new Applied Materials partnership and strong financials despite tariff noise.
EL.PA · Earnings Call · 2026-07-28
A Strategic Pivot into Oculomics
EssilorLuxottica's H1 2026 earnings call marked a definitive shift in narrative. Revenue grew 9.7% at constant currency and operating profit rose 15%, but the real story is the company's ambition to redefine its business around eye-related biomarkers and healthcare delivery. As CEO Francesco Milleri put it, the company is moving "towards the new frontier of oculomics." This is not incremental; it's a strategic pivot. The opening of the first LensCrafters vision and eye health surgery center in Philadelphia, paired with Heidelberg OCT and RetinAI capabilities, signals a move into primary care. Milleri emphasized the reach: "A single 15-minute exam at one location... will be able to detect a wide span of diseases."
We are taking a precise and ambitious direction. EssilorLuxottica is leveraging its unique platform, vertically integrated, fully omnichannel, leading insights and global footprint to move towards the new frontier of oculomics.
To support this, the company announced a strategic partnership with Applied Materials to jointly develop and manufacture next-generation intelligent optical systems for AI and AR wearables. This is a company-unique move that vertically integrates semiconductor-grade manufacturing with optics, positioning EL as a supplier to the entire smart eyewear ecosystem, not just a consumer brand. The partnership goes beyond product development; it's about owning a critical component layer. As Milleri explained, they aim to become "a strategic supplier of a key component that any other manufacturer... have to buy from us."
Wearables and Myopia: Scaling the Innovation Pipeline
The wearables story continues to be a growth engine, but the tone has shifted from dilution to profitability. Meta glasses are scaling across price points, with a new collection targeting younger, price-sensitive consumers. CFO Stefano Grassi noted that all KPIs for smart glasses are improving year over year, including average price, lens penetration, and productivity. This contrasts with prior commentary; in July 2025, Francesco had said, "Meta, also with less margin is making a lot of money" (prior quote), but now the margin profile is clearly inflecting upward.
Nuance Audio, the hearing-aid glasses, is also advancing. The second generation launches mid-September with better battery life and amplification. This product, combined with myopia management, forms the core of the innovation pipeline. Myopia management sales grew 25% in H1, with Stellest now in 11,000 U.S. doors—up from 4,000 just six months ago, as Paul du Saillant highlighted on the prior call. The new R&D hub in Thailand and wearable production in Italy further industrialize the platform.
“In the U.S., Stellest has already reached 11,000 doors across channels” — Paul du Saillant, Deputy CEO · 2026-07-28 — a clear acceleration from the 4,000 trained doors cited in February. This is not just a product launch; it's building a new standard of care.
Financials: Clean Execution Amid Tariff Noise
Financially, the company is delivering. Free cash flow came in at €1.067 billion, the strongest H1 in five years. Tariffs were a net positive 60 basis points to gross margin, thanks to refunds, and Grassi expects more could come in H2. "The net impact of those two things... accounts for 60 basis points in our profit and loss" “the net impact of those two things... accounts for 60 basis points in our profit and loss.” — Stefano Grassi, Chief Financial Officer (CFO) · 2026-07-28 Operating expenses improved 80 basis points despite heavy investment in medtech and innovation.
The company is executing on all fronts: core business growing mid-single-digit, Asia Pacific up 17% constant, and DTC comps strong. With a clear vision and a tech-enabled moat, EssilorLuxottica is no longer just an eyewear maker—it's positioning itself as a leader in preventive healthcare through the lens.
“Together with Meta, we also launched a new collection specifically designed to open the eyeglasses category to a broader, younger and price-sensitive audience.” — Francesco Milleri, Group Chairman and CEO · 2026-07-28 This is a smart segmentation play that keeps the flagship brands premium while expanding the total addressable market.
In summary, this is a company in transition, but one with the financial muscle and strategic clarity to pull it off. The pivot to oculomics and the applied materials partnership are genuinely new and unique to this company, setting it apart from its consumer discretionary peers.